SI21259A - Farmacevtski pripravki z antibiotičnim delovanjem - Google Patents
Farmacevtski pripravki z antibiotičnim delovanjem Download PDFInfo
- Publication number
- SI21259A SI21259A SI200300194A SI200300194A SI21259A SI 21259 A SI21259 A SI 21259A SI 200300194 A SI200300194 A SI 200300194A SI 200300194 A SI200300194 A SI 200300194A SI 21259 A SI21259 A SI 21259A
- Authority
- SI
- Slovenia
- Prior art keywords
- sodium
- potassium
- citrate
- tribasic
- arginine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Opisana je uporaba določenih soli in amino kislin kot stabilizatorja antibiotika Fosfomicin Trometamola in farmacevtski pripravki, ki jih vsebujejo.ŕ
Description
Sedanja iznajdba obravnava uporabo določenih soli in amino kislin kot stabilizatorjev antibiotika Fosfomicin Trometamol in farmacevtskih pripravkov, kijih vsebujejo.
Fosfomicin Trometamol (spodaj FT) (Indeks Merck-a XIII izdaja, št. 4277, stran 755) je znani antibiotik, ki se uporablja za zdravljenje infekcij is sečil in je aktivna sestavina, na primer, zdravila z imenom MONURIL®.
FT je relativno nestabilna spojina, ker vsebuje reaktivno funkcionalno skupino in lahko zaradi temperature in vlažnosti hitro razpade. To otežuje shranjevanje surovin, izdelavo in pripravo farmacevtskih spojin (danes izključno v obliki vodotopnega granulata) in shranjevanje gotovih zavitkov.
2o Pri uporabi se granulat raztopi v vodi in popije. Tudi kislost želodca lahko povzroči obsežen pojav razpadanja, ki praktično zniža količino aktivne sestavine za absorpcijo.
Sedaj smo presenetljivo odkrili, da so nekatere snovi, kadar se uporabijo v mešanici s FT, sposobne stabilizirati antibiotik in s tem olajšajo njegovo uporabo v postopkih farmacevtske tehnologije in za daljši čas stabilizirajo gotove zavitke.
Nadalje se razpad FT pri pH želodčnega soka zmanjša, kadar je FT povezan s temi snovmi. Zato je predmet sedanje iznajdbe uporaba snovi, izbrane izmed naslednjih spojin:
tribazni natrijev ali kalijev citrat monokislinski natrijev ali kalijev citrat
- tribazni natrijev ali kalijev fosfat monokislinski natrijev ali kalijev fosfat natrijev ali kalijev karbonat natrijev ali kalijev bikarbonat natrijev ali kalijev tartrat
- arginin lizin ali njihove mešanice, za stabiliziranje Fosfomicin Trometamola.
Drugi predmet sedanje iznajdbe so farmacevtski pripravki, ki vsebujejo
Fosfomicin Trometamol, spojino izbrano izmed naslednjih: tribazni natrijev ati kalijev citrat monokislinski natrijev ali kalijev citrat tribazni natrijev ali kalijev fosfat
- monokislinski natrijev ali kalijev fosfat
- natrijev ali kalijev karbonat
- natrijev ali kalijev bikarbonat
- natrijev ali kalijev tartrat
- arginin
- lizin ali njihove mešanice, in pomožne snovi, primerne za farmacevtsko uporabo.
Spodaj bodo snovi, čigar uporaba je predmet iznajdbe, skupno 10 imenovane kot stabilizator, kar bo pomenilo tudi mešanice iz dveh ali večih snovi. Količina stabilizatorja za uporabo je med 10% in 100% v molih glede na FT, po možnosti med 30% in 70% in še bolje okoli 50%. Med zgoraj naštetimi stabilizatorji so sedaj najbolj zaželeni tribazni natrijev citrat, natrijev ali kalijev karbonat ali bikarbonat in arginin.
Farmacevtski pripravki, ki so predmet iznajdbe, so pripravljeni iz FT in stabilizatorja z dodajanjem pomožnih snovi za farmacevtsko uporabo.
Sedaj najbolj zaželena farmacevtska oblika FT je oblika vodotopnih granul, ker je zaradi relativno velike količine FT za vnos glede na trenutno dovoljeno količino (5,631 g) raztopina, pridobljena z raztapljanjem granul v vodi, najprimernejša in jo pacienti dobro sprejemajo.
Z novimi pripravki te iznajdbe je možno pridobiti oblike v granulah, možno pa je tudi pripraviti vodotopne pripravke, pridobljene s preprostim primešanjem FT, stabilizatorja in drugih pomožnih snovi, če so potrebne.
Primerne pomožne snovi za pripravo vodotopnih pripravkov vsebujejo FT in stabilizator so, na primer, naravna kot tudi umetna sladila ali arome.
Možno je celo dodati nadaljne pomožne snovi, uporabne na primer za postopek granulacije, vendar njihova uporaba ni nujna. Izdelava pripravkov te iznajdbe lahko ustrezno poteka na različne načine. Možno je, na primer, pripraviti polizdelani granulat FT, ki se mu postopno primeša stabilizator, aromo in sladilo in se v končni fazi celoten izdelek razpošlje v vrečkah.
Po drugem načinu se vse sestavine izdelka lahko direktno zmeša skupaj.
Za boljšo ponazoritev sedanje iznajdbe so podani naslednji primeri.
Primer 1
Stabilizacija FT z izbranimi stabilizatorji se je ocenila eksperimentalno s is tehnologijo DSC. Mehansko mešanico FT (0,02 mola) z vsakim izmed stabilizatorjev (0,01 mola) se je zmešalo z 0,05% vode glede na FT. Tehnologija DSC, uporabljena za vsako mešanico (skeniranje 10°C/min.), omogoča merjenje reakcijske toplote, ki se razvije po talilnem vrhu FT zaradi reakcije razpadanja. Znižana količina razvite toplote kaže na višjo stabilizacijo, če je količina FT enaka.
Dobili smo naslednje vrednosti:
FT (posamezna snov) = 271,03 ± 16,73 (J/g)
FT + natrijev citrat tribazni (dihidrat) = 119,19 ± 7,47 (J/g)
FT + natrijev bikarbonat = 143,32 ±4,92 (J/g)
FT + natrijev karbonat = 115,84 ±9,89 (J/g)
FT + arginin = 175,25 ±9,41 (J/g)
Dobljeni podatki prikazujejo, da se je FT učinkovito stabiliziral z s dodajanjem zgoraj omenjenih snovi. Toplota rekcije razpadanja pri enaki količini FT seje znižala v procentih med okoli 35 in 70%.
Primer 2
Stabilizacijo FT v simuliranem želodčnem soku se je ocenilo s io posnemanjem pogojev pacienta: 5,631 g FT se je dodalo 0,01 mola izbranega stabilizatorja in se oboje raztopilo v vodi (180 ml). Raztopino se je zlilo v simulirani želodčni sok (100 ml, pH 1) in se razpadanje izmerilo kot procent obnove aktivne sestavine v določenem času. Že po 30 minutah je obnova FT brez stabilizatorja znašala 82%, med tem ko je is obnova s stabilizatorjem znašala 90%.
Primer 3
Naslednje farmacevtske pripravke se je pripravilo s preprostim primešanjem sestavin.
Pripravek 1
Fosfomicin Trometamol 5,631 g natrijev citrat dihidrat
1,125 g
aspartam | 0,100 g |
aroma mandarine | 0,100 g |
aroma pomaranče | 0,100 g |
Pripravek 2 | |
Fosfomicin Trometamol | 5,631 g |
natrijev citrat dihidrat | 0,500 g |
natrijev bikarbonat | 0,840 g |
aspartam | 0,100 g |
aroma mandarine | 0,100 g |
aroma pomaranče | 0,100 g |
Pripravek 3 | |
Fosfomicin Trometamol | 5,631 g |
natrijev bikarbonat | 1,127 g |
natrijev karbonat | 0,200 g |
saharoza | 2,000 g |
aroma mandarine | 0,100 g |
aroma limone | 0,100 g |
Pripravek 4
Fosfomicin Trometamol 5,631 g natrijev citrat dihidrat 0,734 g
natrijev citrat monokislina | 0,987 g |
fruktoza | 2,500 g |
aroma mandarine | 0,100 g |
aroma limone | 0,100 g |
Pripravek 5 | |
Fosfomicin Trometamol | 5,631 g |
L-arginin | 1,470 g |
natrijev saharin | 0,010 g |
saharoza | 2,100 g |
aroma mandarine | 0,100 g |
aroma pomaranče | 0,100 g |
Pripravek 6 | |
Fosfomicin Trometamol | 5,631 g |
L-arginin | 0,500 g |
lizin | 0,100 g |
aspartam | 0,100 g |
aroma mandarine | 0,100 g |
aroma pomaranče | 0,070 g |
Pripravek 7
Fosfomicin Trometamol 5,631 g
5 | natrijev citrat dihidrat natrijev karbonat aspartam aroma mandarine aroma pomaranče | 0,500 g 0,500 g 0,100g 0,070 g 0,070 g |
Pripravek 8 Fosfomicin Trometamol | 5,631 g | |
natrijev citrat dihidrat | 1,000 g | |
10 | L-arginin | 0,500 g |
aspartam | 0,070 g | |
aroma pomaranče | 0,150 g | |
aroma limone | 0,030 g | |
15 | Pripravek 9 | |
Fosfomicin Trometamol | 5,631 g | |
natrijev citrat dihidrat | 1,800 g | |
natrijev saharin | 0,040 g | |
šaha roza | 1,500 g | |
20 | aroma mandarine | 0,100 g |
aroma limone | 0,100 g |
Pripravek 10 | |
Fosfomicin Trometamol | 5,631 g |
natrijev citrat dihidrat | 1,125 g |
sorbitol | 1,000 g |
aspartam | 0,070 g |
aroma mandarine | 0,100 g |
aroma pomaranče | 0,100 g |
Claims (8)
- PATENTNI ZAHTEVKI1. Uporaba snovi, izbrane izmed naslednjih:- tribazni natrijev ali kalijev citrat5 - monokislinski natrijev ali kalijev citrat- tribazni natrijev ali kalijev fosfat- monokislinski natrijev ali kalijev fosfat- natrijev ali kalijev karbonat- natrijev ali kalijev bikarbonat io - natrijev aii kalijev tartrat- arginin- lizin ali njihove mešanice, za stabiliziranje Fosfomicin Trometamola.
- 2. Uporaba stabilizatorja spojine po zahtevku 1, označene s tem, da je spojina izbrana izmed tribaznega natrijevega citrata, natrijevega karbonata ali arginina.
- 3. Uporaba stabilizatorja spojine po zahtevku 1, označene s tem,-1111 da se spojina uporabi v molarnem razmerju glede na vsebovani FT med 10% in 100%, po možnosti med 30% in 70% in še bolje okoli 50%.
- 4. Farmacevtski pripravki, ki vsebujejo Fosfomicin Trometamol, spojino s izbrano izmed naslednjih:- tribazni natrijev ali kalijev citrat- monokislinski natrijev ali kalijev citrat- tribazni natrijev ali kalijev fosfat- monokislinski natrijev ali kalijev fosfat io - natrijev ali kalijev karbonat- natrijev ali kalijev bikarbonat- natrijev ali kalijev tartrat- arginin- lizin is ali njihove mešanice, in pomožne snovi, primerne za farmacevtsko uporabo.
- 5. Pripravek po zahtevku 4 v obliki topnega granulata.20
- 6. Pripravek po zahtevku 5, pri 6emer je količina vsebovanega FT za en odmerek 5,631 g.-1212
- 7. Pripravek po zahtevku 4. pri čemer je snov s stabiiizirnim delovanjem izbrana izmed tribaznega natrijevega citrata, natrijevega karbonata in arginina.
- 8. Pripravek po zahtevku 4. pri čemer se snov s stabiiizirnim delovanjem uporabi v molarnem razmerju glede na vsebovani FT med 10% in 100%, po možnosti med 30% in 70% in še bolje okoli 50%,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001725A ITMI20021725A1 (it) | 2002-08-01 | 2002-08-01 | Composizioni farmaceutiche ad attivita' antibiotica. |
Publications (2)
Publication Number | Publication Date |
---|---|
SI21259A true SI21259A (sl) | 2004-02-29 |
SI21259B SI21259B (sl) | 2012-12-31 |
Family
ID=27638551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200300194A SI21259B (sl) | 2002-08-01 | 2003-07-24 | Farmacevtski pripravki z antibiotičnim delovanjem |
Country Status (29)
Country | Link |
---|---|
US (1) | US7303755B2 (sl) |
JP (1) | JP4395338B2 (sl) |
KR (1) | KR100966977B1 (sl) |
AT (1) | AT500521B1 (sl) |
BE (1) | BE1017903A3 (sl) |
BR (1) | BRPI0302496C1 (sl) |
CA (1) | CA2434927C (sl) |
CH (1) | CH696718A5 (sl) |
CO (1) | CO5480297A1 (sl) |
CZ (1) | CZ305023B6 (sl) |
DE (1) | DE10334820B4 (sl) |
DK (1) | DK178348B1 (sl) |
ES (1) | ES2224869B1 (sl) |
FI (1) | FI120080B (sl) |
FR (1) | FR2852845B1 (sl) |
GR (1) | GR20030100300A (sl) |
HR (1) | HRP20030618B1 (sl) |
HU (1) | HU230575B1 (sl) |
IL (1) | IL156615A (sl) |
IT (1) | ITMI20021725A1 (sl) |
NL (1) | NL1023790C2 (sl) |
PL (1) | PL209644B1 (sl) |
PT (1) | PT102995B (sl) |
RU (1) | RU2333000C2 (sl) |
SE (1) | SE527466C2 (sl) |
SI (1) | SI21259B (sl) |
SK (1) | SK287201B6 (sl) |
TR (1) | TR200301248A2 (sl) |
ZA (1) | ZA200305040B (sl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE740685C (de) * | 1941-04-11 | 1943-10-26 | Voigt & Haeffner Ag | Viertakt-Regelschalter fuer Parallel-, Einzel- und Reihenschaltung von Heizwiderstaenden |
ES2244333B1 (es) * | 2004-05-18 | 2006-08-01 | Simbec Iberica, Sl | Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos. |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
NZ598170A (en) | 2009-10-02 | 2014-06-27 | Boehringer Ingelheim Int | Pharmaceutical compositions comprising bi-1356 and metformin |
EA021876B1 (ru) * | 2010-09-20 | 2015-09-30 | ЛИМОНОВ, Виктор Львович | Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения |
ES2385158B1 (es) * | 2010-12-24 | 2013-05-28 | Arafarma Group, S.A. | Composición farmacéutica de fosfomicina |
CN102579466A (zh) * | 2011-01-10 | 2012-07-18 | 王乐 | 一种磷霉素或磷霉素精氨酸盐与精氨酸的组合物 |
US8604078B2 (en) * | 2011-04-06 | 2013-12-10 | Carlos Picornell Darder | Fosfomycin pharmaceutical composition |
US20140323443A1 (en) * | 2013-04-30 | 2014-10-30 | Fresenius Kabi Usa, Llc | Tigecycline formulations |
ITTO20130839A1 (it) * | 2013-10-16 | 2015-04-17 | C & G Farmaceutici S R L | Composizione a base di fosfomicina trometamolo |
DE102014218913A1 (de) | 2014-09-19 | 2016-03-24 | Heraeus Medical Gmbh | Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver |
CN104546689B (zh) * | 2015-01-07 | 2019-01-25 | 同方药业集团有限公司 | 一种含有甲硝唑的药物组合物 |
US20180360855A1 (en) | 2015-12-25 | 2018-12-20 | Yusuf Toktamis ÖGÜN | The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections |
CA3147662A1 (en) | 2021-02-10 | 2022-08-10 | Labiana Health, S.L. | New fosfomycin tablet formulations |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3852434A (en) * | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
IT1161974B (it) | 1978-02-02 | 1987-03-18 | Italchemi Spa | Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono |
IT1112282B (it) | 1978-07-19 | 1986-01-13 | Zambon Spa | Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato |
IT1124610B (it) | 1979-10-18 | 1986-05-07 | Zambo Spa | Mono(2-ammonio-2-idrossimetil-1,3-propandiolo) (2r-cis)-(o-metilossiranil)fosfonato |
JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
CH660305A5 (de) * | 1984-10-05 | 1987-04-15 | Schering Spa | Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren. |
US5182274A (en) * | 1988-09-26 | 1993-01-26 | Teijin Limited | Stabilized aqueous preparation of active form of vitamin d3 |
IT1231013B (it) * | 1989-07-27 | 1991-11-08 | Zambon Spa | Mono (2 ammonio 2 idrossimetil 1,3 propandiolo)(2r,cis) 1,2 epossipropil fosfonato avente migliorate caratteristiche di stabilita' e lavorabilita'. |
US5191094A (en) * | 1989-07-27 | 1993-03-02 | Zambon Group S.P.A. | Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing |
IT1244543B (it) | 1991-02-01 | 1994-07-15 | La Fa Re Srl | Uso topico della fosfomicina e dei suoi sali nella terapia delle infezioni vaginali e/o uretrali |
FR2690340B1 (fr) | 1992-04-24 | 1995-02-24 | Scr Newmed | Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant. |
CA2091152C (en) | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
DE4327063A1 (de) * | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
CA2153553A1 (en) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
JPH09183730A (ja) * | 1995-05-10 | 1997-07-15 | Meiji Seika Kaisha Ltd | ホスホマイシン鏡像異性体を含んでなる医薬 |
DE19712565A1 (de) | 1997-03-25 | 1998-10-01 | Thomas W Dr Stief | Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes |
EP1294361B1 (en) * | 2000-06-21 | 2011-05-25 | Cubist Pharmaceuticals, Inc. | Compositions and methods to improve the oral absorption of antimicrobial agents |
WO2002032459A2 (en) * | 2000-10-17 | 2002-04-25 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
US7378408B2 (en) | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
TW200403240A (en) * | 2002-06-28 | 2004-03-01 | Upjohn Co | Difluorothioacetamides of oxazolidinones as antibacterial agents |
-
2002
- 2002-08-01 IT IT001725A patent/ITMI20021725A1/it unknown
-
2003
- 2003-06-24 IL IL156615A patent/IL156615A/en active IP Right Grant
- 2003-06-27 ZA ZA200305040A patent/ZA200305040B/xx unknown
- 2003-07-01 NL NL1023790A patent/NL1023790C2/nl not_active IP Right Cessation
- 2003-07-07 PT PT102995A patent/PT102995B/pt active IP Right Grant
- 2003-07-10 US US10/615,781 patent/US7303755B2/en not_active Expired - Lifetime
- 2003-07-10 CA CA2434927A patent/CA2434927C/en not_active Expired - Lifetime
- 2003-07-11 CO CO03058787A patent/CO5480297A1/es active IP Right Grant
- 2003-07-15 CH CH01238/03A patent/CH696718A5/it not_active IP Right Cessation
- 2003-07-15 GR GR20030100300A patent/GR20030100300A/el unknown
- 2003-07-16 FI FI20031078A patent/FI120080B/fi active IP Right Grant
- 2003-07-22 DK DK200301097A patent/DK178348B1/da not_active IP Right Cessation
- 2003-07-23 JP JP2003200437A patent/JP4395338B2/ja not_active Expired - Lifetime
- 2003-07-24 SI SI200300194A patent/SI21259B/sl active Search and Examination
- 2003-07-25 SE SE0302129A patent/SE527466C2/sv not_active IP Right Cessation
- 2003-07-28 AT AT0119103A patent/AT500521B1/de not_active IP Right Cessation
- 2003-07-28 BE BE2003/0427A patent/BE1017903A3/fr not_active IP Right Cessation
- 2003-07-29 BR BRPI0302496A patent/BRPI0302496C1/pt active IP Right Grant
- 2003-07-30 ES ES200301811A patent/ES2224869B1/es not_active Expired - Fee Related
- 2003-07-30 HR HR20030618A patent/HRP20030618B1/xx not_active IP Right Cessation
- 2003-07-30 DE DE10334820.4A patent/DE10334820B4/de not_active Expired - Lifetime
- 2003-07-31 PL PL361518A patent/PL209644B1/pl unknown
- 2003-07-31 SK SK976-2003A patent/SK287201B6/sk not_active IP Right Cessation
- 2003-07-31 RU RU2003124299/15A patent/RU2333000C2/ru active
- 2003-07-31 FR FR0309459A patent/FR2852845B1/fr not_active Expired - Lifetime
- 2003-07-31 HU HU0302441A patent/HU230575B1/hu unknown
- 2003-07-31 KR KR1020030053032A patent/KR100966977B1/ko active IP Right Grant
- 2003-08-01 CZ CZ2003-2096A patent/CZ305023B6/cs not_active IP Right Cessation
- 2003-08-01 TR TR2003/01248A patent/TR200301248A2/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU609988B2 (en) | Pharmaceutical compositions | |
CA1275933C (en) | Therapeutic composition containing ibuprofen | |
JP2735903B2 (ja) | イブプロフエン沸騰製剤 | |
US6432450B1 (en) | Effervescent granules with delayed effervescent effect | |
AU2006257072B2 (en) | Diclofenac formulations and methods of use | |
ES2223135T3 (es) | Composiciones farmaceuticas que contienen vitamina d y calcio, su preparacion y su uso terapeutico. | |
SI21259A (sl) | Farmacevtski pripravki z antibiotičnim delovanjem | |
HU206265B (en) | Process for producing pharmaceutical compositions comprising morphine | |
IE892047L (en) | Effervescent histamine h2 - antagonist composition | |
AU2017203009A1 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
EP1747781B1 (en) | Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients | |
WO2005011639A2 (en) | Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use | |
WO2024005767A1 (en) | A taste masked solid composition of zinc active | |
GR1010127B (el) | Αναβραζοντα κοκκια που περιεχουν αλατα μαγνησιου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20121108 |